This week's challenge asks entrants to design an Ozempic-like drug, and the new site is built to help newcomers start designing proteins quickly.
Recap by typeshit. Post by Julian Englert on X.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
ASN Publications describes a patient taking both drugs who had a kidney injury and then developed life-threatening acidosis. Worth reading for the clinical details.
The Times reports plans that could put Wegovy on Ireland's public health service, a potential shift in who can get the drug without paying privately.
Loading…